The price is really a field bet, on improving the tolerance of antibody-drug conjugates, by oncology patients, as the same come to market. Here's the Buffalo presser from last week:
. . .BUFFALO, N.Y. – Abceutics, Inc., a startup preclinical-stage biopharmaceutical company that was spun out of the laboratory of University at Buffalo researcher Joseph P. Balthasar, PhD, has been acquired by the global biopharmaceutical company Merck. . . .
Merck acquired Abceutics for a potential consideration of up to $208 million, including contingent milestone payments based upon the progress of candidates under the agreement. . . .
The company’s core technology was licensed from University at Buffalo. The technology has been developed through grants from the National Institutes of Health, as well as $110,000 from the Buffalo Innovation Accelerator Fund, which is operated by UB’s Business and Entrepreneur Partnerships office.
Abceutics has operated out of incubator space in UB’s New York State Center of Excellence in Bioinformatics and Life Sciences, which also provided the company $50,000 from Empire State Development’s Division of Science, Technology and Innovation. Additionally, the company has benefitted from the National Science Foundation’s Innovation Corps program at UB. . . .
We should expect quite a few milestones-based deals in this space, in the coming years.
And, now. . . onward into the bright sunshine here -- after UConn let me sweep every March Madness pool I entered. . . and, so sorry it is soggy in Music City. Smile, just the same. . . .
नमस्ते
No comments:
Post a Comment